GTH Stock Overview
Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genetron Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.03 |
| 52 Week High | US$4.05 |
| 52 Week Low | US$2.08 |
| Beta | 0.50 |
| 11 Month Change | 2.68% |
| 3 Month Change | 9.38% |
| 1 Year Change | 37.59% |
| 33 Year Change | -93.70% |
| 5 Year Change | n/a |
| Change since IPO | -91.61% |
Recent News & Updates
Recent updates
Genetron Holdings GAAP EPS of -$0.08, revenue of $20.56M
Oct 12China's Genetron gets acquisition offer from co-founder/CEO
Aug 22Are Investors Undervaluing Genetron Holdings Limited (NASDAQ:GTH) By 27%?
Dec 07
Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 17Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22
Mar 27Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?
Feb 25Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China
Jan 06Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China
Nov 27Genetron (GTH) Investor Presentation - Slideshow
Nov 18Genetron Holdings reports Q3 results
Nov 09Shareholder Returns
| GTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | -1.9% | 0.5% |
| 1Y | 37.6% | 10.4% | 20.5% |
Return vs Industry: GTH exceeded the US Biotechs industry which returned 8.2% over the past year.
Return vs Market: GTH exceeded the US Market which returned 25.8% over the past year.
Price Volatility
| GTH volatility | |
|---|---|
| GTH Average Weekly Movement | 1.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GTH has not had significant price volatility in the past 3 months.
Volatility Over Time: GTH's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 993 | Sizhen Wang | www.genetronhealth.com |
Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People’s Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors.
Genetron Holdings Limited Fundamentals Summary
| GTH fundamental statistics | |
|---|---|
| Market cap | US$127.29m |
| Earnings (TTM) | -US$111.74m |
| Revenue (TTM) | US$89.95m |
1.4x
P/S Ratio-1.1x
P/E RatioIs GTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTH income statement (TTM) | |
|---|---|
| Revenue | CN¥650.71m |
| Cost of Revenue | CN¥369.28m |
| Gross Profit | CN¥281.43m |
| Other Expenses | CN¥1.09b |
| Earnings | -CN¥808.40m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -25.56 |
| Gross Margin | 43.25% |
| Net Profit Margin | -124.23% |
| Debt/Equity Ratio | 15.7% |
How did GTH perform over the long term?
See historical performance and comparison